Literature DB >> 21111994

Hematologic and oncologic diseases and the liver.

Marvin M Singh1, Paul J Pockros.   

Abstract

Malignant and nonmalignant disorders may affect the liver, causing signs and symptoms ranging from mild increases of liver tests to fulminant hepatic failure. This article discusses the most common hematologic and oncologic disorders and their effect on the liver. The section on nonmalignant hematologic disorders includes the anemias, paroxysmal nocturnal hemoglobinuria, disseminated intravascular coagulation, malaria, Banti syndrome, the porphyrias, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. Malignant hematologic conditions include leukemias, lymphomas, and myeloproliferative disorders. Other conditions causing portal hypertension and hepatic metastases are also discussed. The most commonly encountered hepatic manifestations of hematologic and oncologic disorders are reviewed.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21111994     DOI: 10.1016/j.cld.2010.09.013

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  6 in total

1.  Efficient and Highly Accurate Diagnosis of Malignant Hematological Diseases Based on Whole-Slide Images Using Deep Learning.

Authors:  Chong Wang; Xiu-Li Wei; Chen-Xi Li; Yang-Zhen Wang; Yang Wu; Yan-Xiang Niu; Chen Zhang; Yi Yu
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

2.  Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: a single-center retrospective cohort study.

Authors:  Andry Van de Louw; Kathleen Twomey; Nicholas Habecker; Kevin Rakszawski
Journal:  Ann Hematol       Date:  2020-09-12       Impact factor: 3.673

3.  Postoperative mortality and need for transitional care following liver resection for metastatic disease in elderly patients: a population-level analysis of 4026 patients.

Authors:  Sonia T Orcutt; Avo Artinyan; Linda T Li; Eric J Silberfein; David H Berger; Daniel Albo; Daniel A Anaya
Journal:  HPB (Oxford)       Date:  2012-09-28       Impact factor: 3.647

4.  Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.

Authors:  Andreas Seeber; Agnieszka Martowicz; Gilbert Spizzo; Thomas Buratti; Peter Obrist; Dominic Fong; Guenther Gastl; Gerold Untergasser
Journal:  BMC Cancer       Date:  2015-05-07       Impact factor: 4.430

Review 5.  Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.

Authors:  James H Lewis; Sophia K Khaldoyanidi; Carolyn D Britten; Andrew H Wei; Marion Subklewe
Journal:  Am J Clin Oncol       Date:  2022-07-18       Impact factor: 2.787

6.  Hepatic manifestations in hematological disorders.

Authors:  Jun Murakami; Yukihiro Shimizu
Journal:  Int J Hepatol       Date:  2013-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.